Skip to main content
Premium Trial:

Request an Annual Quote

At Chips to Hits, Genzyme Official Bemoans PGx Media Hype

BOSTON, Sept. 14 (GenomeWeb News) - A Genzyme official charged that mainstream media outlets have been "whipping everybody up about personalized medicine's promise" and urged the pharmacogenomics community to "be more realistic" about the future of the field.

 

Robert Yocher, Genzyme's vice president of regulatory affairs, told attendees of IBC's Chips to Hits conference here today that the idea that a patient could go to a drugstore bearing a chip with his or her biological information on it and receive personalized treatment "is not going to happen in our lifetime or our kids' lifetimes." Yocher spoke during a joint US Food and Drug Administration and industry panel discussion at the conference.

 

Although he said his optimism about the future of PGx is "tremendous," Yocher said in an interview after his talk that bringing a test to market is a "tough, tough decision" for in vitro diagnostic developers, and that tests in development today would most likely take 10 to 15 years to reach the marketplace, rather than two or three. He noted that the timeline may be shorter for companies trying to bring oncology-focused tests to market.

 

Yocher placed much of the blame for the promise of a short time to market on "media hype" from "weekly news magazines like Newsweek, as well as trade magazines and newspapers" that create "unrealistic expectations" in the industry and cause, in his opinion, the FDA to "rush" guidance documents to the public. Yocher said he expects the FDA to release "dozens" of new guidance documents over the next decade and said that "what we think is valid now is probably going to change tomorrow."

 

Yocher also urged the pharmacogenomics community to police its message by writing letters to the editors of publications that "hype" the promise of personalized medicine and to collaborate more effectively to encourage progress in the industry.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.